This document discusses post-marketing surveillance (PMS), which involves monitoring the safety of pharmaceutical drugs after they have been approved and released on the market. PMS is important because pre-approval clinical trials involve relatively small groups of patients and may miss rare or long-term adverse effects only seen in larger populations. The document outlines various methods for PMS, including spontaneous reporting, cohort studies, and case-control studies. It also discusses the benefits of PMS for improving product quality and safety monitoring, as well as manufacturers' role in establishing PMS procedures and evaluating feedback.
PMS are the studies done after the drug is marketed to ensure the safety and efficacy of drugs. Here detailed about the need for PMS, sources of informations and methods of PMS
The Investigator's Brochure (IB) is a comprehensive document summarizing the body of information about an investigational product (IB) obtained during a drug trial.
PMS are the studies done after the drug is marketed to ensure the safety and efficacy of drugs. Here detailed about the need for PMS, sources of informations and methods of PMS
The Investigator's Brochure (IB) is a comprehensive document summarizing the body of information about an investigational product (IB) obtained during a drug trial.
Abbreviated New Drug Application [ANDA]Sagar Savale
An Abbreviated New Drug Application (ANDA) contains data which when submitted to FDA's CDER, Office of Generic Drugs, provides for the review and ultimate approval of a generic drug product.
Unit-III, Chapter 1. Registration of Indian Products in Overseas Market.Audumbar Mali
Unit-III, Chapter 1. Registration of Indian Products in Overseas Market.
B. Pharm. Final Year, Sem-VIII, BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory),
As PCI Syllabus.
Abbreviated New Drug Application [ANDA]Sagar Savale
An Abbreviated New Drug Application (ANDA) contains data which when submitted to FDA's CDER, Office of Generic Drugs, provides for the review and ultimate approval of a generic drug product.
Unit-III, Chapter 1. Registration of Indian Products in Overseas Market.Audumbar Mali
Unit-III, Chapter 1. Registration of Indian Products in Overseas Market.
B. Pharm. Final Year, Sem-VIII, BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory),
As PCI Syllabus.
Post Marketing Surveillance and Pharmacoepidemiologyijtsrd
Post Marketing Surveillance PMS and pharmacoepidemiology are essential components of drug safety monitoring and effectiveness evaluation in real world clinical settings. PMS involves the continuous monitoring of pharmaceutical products after regulatory approval to detect and assess adverse events and safety issues that may not have surfaced during pre marketing clinical trials. Pharmacoepidemiology, on the other hand, employs epidemiological methods to study the effects of drugs in large populations, utilizing real world data from various sources. This article explores the significance of PMS and pharmacoepidemiology in ensuring patient safety, highlights their mutual contributions in research, and underscores the importance of collaborative efforts between regulatory agencies, academia, and pharmaceutical companies. The challenges related to data quality, privacy, and ethical considerations are discussed, along with potential advancements in methodologies and the integration of new technologies for future research and vigilance in drug safety and public health. Dr. Farheen Yousuf "Post-Marketing Surveillance and Pharmacoepidemiology" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-7 | Issue-4, August 2023, URL: https://www.ijtsrd.com/papers/ijtsrd59690.pdf Paper Url:https://www.ijtsrd.com/pharmacy/other/59690/postmarketing-surveillance-and-pharmacoepidemiology/dr-farheen-yousuf
Post Marketing Surveillance and Drug Safety Monitoring Ensuring Patient Well ...ijtsrd
This comprehensive review explores the dynamic landscape of post marketing surveillance and drug safety monitoring, delving into key aspects from definitions to emerging trends. The discussion encompasses the importance of drug safety monitoring in ensuring patient well being, highlighting the significance of real world evidence, artificial intelligence, and patient centric approaches. Case studies provide valuable insights into both successful surveillance instances and lessons learned from challenges. Anticipated developments in the field are examined, underscoring the transformative impact on patient care and industry practices. The conclusion summarizes key takeaways and issues a call to action for stakeholders to embrace enhanced drug safety practices in this evolving landscape. Muhammad Afsana | G. Naga Malleshwari "Post-Marketing Surveillance and Drug Safety Monitoring: Ensuring Patient Well-Being" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-7 | Issue-6 , December 2023, URL: https://www.ijtsrd.com/papers/ijtsrd61198.pdf Paper Url: https://www.ijtsrd.com/pharmacy/other/61198/postmarketing-surveillance-and-drug-safety-monitoring-ensuring-patient-wellbeing/muhammad-afsana
Pharmacovigilance is a scientific discipline concerned with the collection, detection, assessment, monitoring, and prevention of adverse effects of pharmaceutical products.
Pharmacovigilance is a branch of Pharmacoepidemiology and is restricted to the study of adverse effects of drugs.
Post Marketing Surveillance (Regulatory affairs).pptxYuvaraj KG
Postmarketing drug surveillance refers to the monitoring of drugs once they reach the market after clinical trials. It evaluates drugs taken by individuals under a wide range of circumstances over an extended period of time.
These slides will help you to know about post marketing surveillance of drug. What are the major goals. Basic steps involve in post marketing surveillance of a drug. How to design a case stuty etc.
The safe use of medicines is perhaps the single most important criteria that any regulatory authority within a given country has to ensure in order both to protect the public health and the integrity of its health care system. For the same purpose pharmacovigilance was established. According to WHO, Pharmacovigilance is the science and activities related to the collection, detection, and assessment of ADR’s. It promotes the systematic, rational use and assures the confidence for the safety of drugs. It improves patient care and safety. Significance of pharmacovigilance is growing as the patients or consumers have become more responsive about the advantage and hazard of medicines. Pharmacovigilance is a complex process and a robust system is essential to undertake the activity. A good pharmacovigilance system will identify the hazard aspects in the short period of time. This review article tries to explain the some basic principles, history and developments, methods and some scope of this developing field i.e. Pharmacovigilance in India.
ICH Guidelines for Pharmacovigilance.pdfNEHA GUPTA
The "ICH Guidelines for Pharmacovigilance" PDF provides a comprehensive overview of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines related to pharmacovigilance. These guidelines aim to ensure that drugs are safe and effective for patients by monitoring and assessing adverse effects, ensuring proper reporting systems, and improving risk management practices. The document is essential for professionals in the pharmaceutical industry, regulatory authorities, and healthcare providers, offering detailed procedures and standards for pharmacovigilance activities to enhance drug safety and protect public health.
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...Levi Shapiro
Letter from the Congress of the United States regarding Anti-Semitism sent June 3rd to MIT President Sally Kornbluth, MIT Corp Chair, Mark Gorenberg
Dear Dr. Kornbluth and Mr. Gorenberg,
The US House of Representatives is deeply concerned by ongoing and pervasive acts of antisemitic
harassment and intimidation at the Massachusetts Institute of Technology (MIT). Failing to act decisively to ensure a safe learning environment for all students would be a grave dereliction of your responsibilities as President of MIT and Chair of the MIT Corporation.
This Congress will not stand idly by and allow an environment hostile to Jewish students to persist. The House believes that your institution is in violation of Title VI of the Civil Rights Act, and the inability or
unwillingness to rectify this violation through action requires accountability.
Postsecondary education is a unique opportunity for students to learn and have their ideas and beliefs challenged. However, universities receiving hundreds of millions of federal funds annually have denied
students that opportunity and have been hijacked to become venues for the promotion of terrorism, antisemitic harassment and intimidation, unlawful encampments, and in some cases, assaults and riots.
The House of Representatives will not countenance the use of federal funds to indoctrinate students into hateful, antisemitic, anti-American supporters of terrorism. Investigations into campus antisemitism by the Committee on Education and the Workforce and the Committee on Ways and Means have been expanded into a Congress-wide probe across all relevant jurisdictions to address this national crisis. The undersigned Committees will conduct oversight into the use of federal funds at MIT and its learning environment under authorities granted to each Committee.
• The Committee on Education and the Workforce has been investigating your institution since December 7, 2023. The Committee has broad jurisdiction over postsecondary education, including its compliance with Title VI of the Civil Rights Act, campus safety concerns over disruptions to the learning environment, and the awarding of federal student aid under the Higher Education Act.
• The Committee on Oversight and Accountability is investigating the sources of funding and other support flowing to groups espousing pro-Hamas propaganda and engaged in antisemitic harassment and intimidation of students. The Committee on Oversight and Accountability is the principal oversight committee of the US House of Representatives and has broad authority to investigate “any matter” at “any time” under House Rule X.
• The Committee on Ways and Means has been investigating several universities since November 15, 2023, when the Committee held a hearing entitled From Ivory Towers to Dark Corners: Investigating the Nexus Between Antisemitism, Tax-Exempt Universities, and Terror Financing. The Committee followed the hearing with letters to those institutions on January 10, 202
Biological screening of herbal drugs: Introduction and Need for
Phyto-Pharmacological Screening, New Strategies for evaluating
Natural Products, In vitro evaluation techniques for Antioxidants, Antimicrobial and Anticancer drugs. In vivo evaluation techniques
for Anti-inflammatory, Antiulcer, Anticancer, Wound healing, Antidiabetic, Hepatoprotective, Cardio protective, Diuretics and
Antifertility, Toxicity studies as per OECD guidelines
Unit 8 - Information and Communication Technology (Paper I).pdfThiyagu K
This slides describes the basic concepts of ICT, basics of Email, Emerging Technology and Digital Initiatives in Education. This presentations aligns with the UGC Paper I syllabus.
Acetabularia Information For Class 9 .docxvaibhavrinwa19
Acetabularia acetabulum is a single-celled green alga that in its vegetative state is morphologically differentiated into a basal rhizoid and an axially elongated stalk, which bears whorls of branching hairs. The single diploid nucleus resides in the rhizoid.
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdfTechSoup
In this webinar you will learn how your organization can access TechSoup's wide variety of product discount and donation programs. From hardware to software, we'll give you a tour of the tools available to help your nonprofit with productivity, collaboration, financial management, donor tracking, security, and more.
Read| The latest issue of The Challenger is here! We are thrilled to announce that our school paper has qualified for the NATIONAL SCHOOLS PRESS CONFERENCE (NSPC) 2024. Thank you for your unwavering support and trust. Dive into the stories that made us stand out!
Introduction to AI for Nonprofits with Tapp NetworkTechSoup
Dive into the world of AI! Experts Jon Hill and Tareq Monaur will guide you through AI's role in enhancing nonprofit websites and basic marketing strategies, making it easy to understand and apply.
Synthetic Fiber Construction in lab .pptxPavel ( NSTU)
Synthetic fiber production is a fascinating and complex field that blends chemistry, engineering, and environmental science. By understanding these aspects, students can gain a comprehensive view of synthetic fiber production, its impact on society and the environment, and the potential for future innovations. Synthetic fibers play a crucial role in modern society, impacting various aspects of daily life, industry, and the environment. ynthetic fibers are integral to modern life, offering a range of benefits from cost-effectiveness and versatility to innovative applications and performance characteristics. While they pose environmental challenges, ongoing research and development aim to create more sustainable and eco-friendly alternatives. Understanding the importance of synthetic fibers helps in appreciating their role in the economy, industry, and daily life, while also emphasizing the need for sustainable practices and innovation.
2. INDEX
Introduction
History
Benefits to a PMS system
Sources of Post-marketing Surveillance
Need of Post-marketing Surveillance (P.M.S)
Vision of Post-marketing Surveillance (P.M.S)
Opportunity
Practical aspects of PMS
PMS procedure
Method of Post-marketing Surveillance
Manufacturer PMS SYSTEM
Possible Achievements
Summary
Reference
3. PHASES OF CLINICAL TRIALS
Phase I :First in man Safety
Phase II: First in Patient –
dose,dosage forms
Phase III: Efficacy , ADRs
Post-marketing Surveillance or
Phase –IV :Evaluation of in the real
clinical setting.
4. INTRODUCTION
To market a drug,the manufacturer must provide evidence
of its efficacy and safety to the U.S.FOOD AND Drug
Administration(FDA)
In Premarketing testing,the numbers and type of patient
used to demonstrate a drug`s efficacy and safety are
limited as compared with the numbers and type of patient
who will eventually be prescribed the drugs after it is
marketed.
Although post-marketing surveillance cannot provide
knowledge of the safety or efficacy of the drug at the time
of there introduction into the market.
Post-marketing surveillance of drug therefore play an
important role to discover an undesirable effect that might
present at risk.
It provide additional informationon the benefit and risk of
the drugs.
5. POST-MARKETING SURVEILLANCE
No fixed duration/Patient population
Starts immediately after marketing
Report all ADRs
Help to detect
Rare ADRs
Drug interaction
Also new uses for drugs[sometimes called
Phase V]
6. HISTORY
In the 1960 at least two serious drugs reactions were
observed in many patient.thalidomide causes limb
deformities(phocomelia).
observed in Japan,was the optic nerve damage(subacute
myelooptic –neuropathy).
The PMA,senator Edward Kennedy (D-Mass.) suggested that
a better system was need for monitoring the use and
effects of prescription drug after they are marketed.
As a result, the joint commissionon Prescription Drugs Use
was established in 1976,funded largely by the drug
industry, with the mandate to design a post-marketing
surveillance system to detect,quantify,and describe the
anticipated and unanticipated effects of marketed drugs.
The delayed discovery of the practolol`s adverse effects
spurred effects to improve post-marketing surveillance.
7. SOURCES OF PMS INFORMATION
The following may be considered as sources
of information, some source are proactive
and some are reactive.
Expert user groups(“ focus groups‟‟)
Customer surveys.
Customer complaints and warranty claims
Post CE-market clinical trials.
Literature reviews.
Device tracking/implant registries.
User reaction during training programmers.
The media.
8. ARE THERE BENEFITS TO A
PMS SYSTEM
Detection of manufacturing problems;
improvement of medical device quality;
verification of risk analysis;
intelligence of long-term performance;
chronic complications;
performance trends;
performance in different user
populations
9. mechanisms the device may be misused.
feedback on indications for
use,instructions for use.
training required for users; use with
other devices.
customer satisfaction .
market performance and sustainability.
identification of incident reports (and
field safety corrective action reports).
10. A manufacturer of intraocular lenses
collected numerous complaints from
users about broken lenses.
The manufacturer assessed the
complaints and deemed them
statistically significant.
11. WHY DO WE NEED POST-
MARKETING SURVEILLANCE
The primary objective of post-marketing surveillance
is to develop information about drug effects under
customary condition of drug use.
Rare adverse events may not be detected in pre-
licensure studies because in very large clinical trials
have limitation.
Access to more patient and given data
Given diversity of data sources, innovative
approaches to retrieval of key data may have great
potential vs. single unified system.
Better background rates,comparable “control‟‟
population.
Increase in “non-medical‟‟ data sources-
e.g.Pharmacy,supermarket,employer vaccination.
12. VISION FOR POST-MARKETING
SURVEILLANCE
All patient‟s vaccination and health
outcomes are immediately and continuously
Accessible in automated database allowing
optimal detection and analysis of potential
problem in vaccine safety.
Not there yet –both major limitation and
opportunities in current health information
system.
Both problems and solution to enhance vaccine
safety information and analysis are applicable to
safety initiatives for other medical products.
13. POST-MARKETING SURVEILLANCE
OPPORTUNITY
Access to additional health system
data.
Access to global
data:regulatory,inspectional,health
system,international surveillance and
pharmacovigilence.
Better analytical tools and methods.
14. PRACTICAL ASPECTS OF PMS
PMS should be proactive.
Manufacturer should document
compliance.
Manufacturer`s PMS procedure
should discuss the information that
will be collected and obtained as a
part of system.
CONT………..
15. ABOUT PMS PROCEDURE
It should assign departments or
position a responsible for performing
a particular function.
Manufacturer may find it helpful to a
have report at the end of year, as
well as PMS tracking schedule and
log.
This information could constitute
feedback received from user .
16. Information obtained from PMS
system should be communicated , at
a minimum, annually during a
management review meeting-which is
top management's examination of the
organization's quality management
system.
17. METHODS OF SURVEILLANCE
Thus, four types of studies are generally used to
identify drugs effects:
1. Controlled clinical trials,
2. Spontaneous or voluntary recording
3. Cohort, studies and
4. Case control studies
1. Controlled clinical trials:
To minimize bias through such method as
randomization and “double-blinding‟‟.
Directly monitor patients for the duration of studies.
For evaluating a drug‟s efficacy and safety.
They are often costly.
18. 2. Spontaneous or voluntary reporting
By physician and other health provider &
hospital may to alert FDA and
pharmaceutical firms to possible adverse
effects of drugs.
3. Cohort studies :
Studies follow a defined group of patient for a
period of time.
Patient are not randomly assigned , & there is
no blinding.
19. If adverse reaction occur. A second group of
patient with the same medical condition ,
who are not taking the drug and who may be
receiving alternative treatment.
4.Case-control studies :
Case control studies identify patient with the
adverse effects to be studied, and compare
them with the sample drawn from the same
cohort that gave rise to cases.
20. MANUFACTURER PMS SYSTEM
These are some of the type of knowledge and
feed back which can achieved from a PMS
system.
Detection of some manufacturing problems.
Product quality improvement.
Conformation (or otherwise) of risk analysis.
Knowledge of long term
performance/reliability and /or chronic
complication.
Knowledge of performance in different user
population. CONTD…..
21. Feedback on indication of use.
Feedback on instruction for use.
Feedback on use with other devices.
Feedback on customer satisfaction.
Identification OF vigilance report.
Feedback on continuing market
viability.
22. SUMMARY
Postmarketing surveillance (PMS) is the
practice of monitoring the safety of a
pharmaceutical drug .
Device after it has been released on the
market and is an important part of the science
of pharmacovigilance.
Since drugs are approved on the clinical trials
which involve relatively small numbers of
people who have been selected for this
purpose . CONTD……..
23. Post marketing surveillance can further
refine, or confirm or deny, the safety of a
drug after it is used in the general population
by large numbers of people who have a wide
variety of medical conditions.
Postmarketing surveillance uses a number of
approaches to monitor the safety of licensed
drugs, including spontaneous reporting
databases, prescription event monitoring,
electronic health records, patient registries and
record linkage between health database.
24. Pre-licesure clinical,product,and
manufacturing data are critical
foundation for evaluating safety and
effectiveness.
However , post-licensure surveillance
is essential to assure product safety.
25. Absence of complete diagnostic
information.
Vaccines and other medical products
have risk that may include rare
serious adverse events not detected.
26. REFERENCE
1. Borden E.K, The upjohn Co., „„POST-
MARKETING SURVEILLANCE OF out patient
drugs using a pharmacy-based registration
system-report of two studies,‟‟ presented at
the drug information association Work shop,
williamsburg va,DECEMBER 1981,10-32.
2. CLARREN S.N.et al, “The evaluabdity
Assessment of the developing experiment in post
marketing surveillance of prescription drugs‟‟,
prepared for the experiment technology incentives
program, National Bureau of standards , 10-22.
27. REFERENCE
2.FOOD AND DRUGS
ADMINISTRATION, „„Supplementary
reports to contracts and grants committee on
Medicaid”, from the division of Drugs
Experience, BUREAU OF DRUGS,1982, 10-32.
3.KAREN MIDTHUN, „„Deputy Director
Centre for biologics Evaluation and
Research”,FDA,ICDRA Pre-conference berne,
SWITZERLAND september 15